Medical Digest & Congress Report

Prof. Evelien Dekker highlights key updates in screening and surveillance protocols for colorectal cancer prevention at the UEG Week 2026 Congress. This brief examines the practical application of the new European guidelines, discussing evidence-based recommendations to optimize risk stratification, refine post-polypectomy surveillance, and enhance quality standards in clinical practice to reduce...

Dr. David Martí-Aguado addresses the clinical challenges surrounding metabolic dysfunction-associated steatohepatitis (MASH) and progressive liver fibrosis at the UEG Week 2026 Congress. This brief outlines the expanding burden of MASH in gastroenterology practice, emphasizing early risk stratification, non-invasive diagnostic strategies, and the emergence of targeted disease-modifying therapies d...

Dr. Naim Alkhouri highlights the critical central role of the liver in cardiometabolic health at the UEG Week 2026 Congress. This brief explores the complex intersections between obesity, metabolic dysfunction-associated steatotic liver disease (MASLD), and MASH, providing gastroenterologists with actionable strategies for early identification, integrated care workflows, and modern therapeutic opt...

Dr. Christopher Ma presents actionable insights on advancing clinical care in Crohn’s disease at the UEG Week 2026 Congress. This brief explores updated management algorithms, emphasizing risk stratification, proactive monitoring, and timely optimization of biologic and novel targeted therapies to achieve durable disease control and improve long-term outcomes for patients with Crohn's disease....

Dr. Manuel Barreiro de Acosta shares key perspectives on navigating the modern therapeutic landscape in ulcerative colitis at the UEG Week 2026 Congress. Focusing on the IL-23 pathway, this brief highlights clinical data and strategic considerations for incorporating IL-23 targeted therapies to achieve durable endoscopic remission and set new standards in patient-centered IBD care. Video: https://...

Prof. Remo Panaccione highlights modern therapeutic strategies in inflammatory bowel disease at the UEG Week 2026 Congress. This brief examines the evolving roles of advanced targeted agents, focusing on the clinical utility of novel JAK inhibitors and IL-23 targeted therapies to achieve deep disease control, optimize long-term patient outcomes, and personalize treatment pathways in IBD. Video: ht...

Prof. Jean-Frédéric Colombel presents key insights on optimizing therapeutic outcomes in ulcerative colitis at the UEG Week 2026 Congress. Drawing from the latest data from the VERDICT trial, this brief explores the clinical rationale for targeting deep endoscopic and histological healing, highlighting strategies to elevate treatment standards, prevent long-term bowel damage, and achieve sustained...

Dr. Caterina Conte presents key takeaways from the EASD e-Learning expert session on obesity at the EASD 2026 Congress. This brief highlights clinical strategies for comprehensive weight management, addressing metabolic comorbidities, and utilizing evidence-based educational frameworks to optimize patient care. Video: https://medicaldigest.org/scientific-contents/interview:easd-e-learning-expert-s...

Dr. Åke Sjöholm presents key insights from the EASD-ESC joint session on advancing cardiovascular protection with incretins and SGLT-2 inhibitors at the EASD 2026 Congress. This brief highlights clinical mechanisms, cardiorenal benefits, and combined therapeutic strategies to reduce cardiovascular risk and improve outcomes in patients with metabolic disease and type 2 diabetes. Video: https://medi...

Dr. Eric Lawitz presents a hepatologist's perspective on altering the trajectory of chronic metabolic disease at the EASD 2026 Congress. This brief highlights the evolving role of GLP-1-based therapies and strategies for integrating targeted liver health management beyond simple steatosis into comprehensive metabolic care. Video: https://medicaldigest.org/scientific-contents/interview:changing...

Dr. Alexandra Kautzky-Willer presents key insights on the patterns and prevention of cardiovascular diseases at the EASD 2026 Congress. This brief highlights clinical strategies for identifying cardiovascular risk patterns, implementing targeted early preventive measures, and optimizing long-term outcomes in patients with metabolic disorders. Video: https://medicaldigest.org/scientific-contents/in...

Dr. Claudio Scafoglio presents key insights into expanding the scope of SGLT-2 inhibition at the EASD 2026 Congress. This brief highlights real-world clinical data, underlying cellular mechanisms, and emerging evidence surrounding potential oncological applications and broader therapeutic frontiers of SGLT-2 inhibitors. Video: https://medicaldigest.org/scientific-contents/interview:sglt-2-inhibito...

Dr. Gian Paolo Fadini presents key insights into interconnected organ protection with SGLT-2 inhibitors at the EASD 2026 Congress. This brief highlights clinical evidence on the cardiovascular, renal, and metabolic benefits of SGLT2 inhibition, emphasizing strategies to reduce overall risk and optimize long-term outcomes in patients with type 2 diabetes. Video: https://medicaldigest.org/scientific...

Dr. Matthias Blüher presents key insights from the EASD-EASO joint session on obesity management through different lenses at the EASD 2026 Congress. This brief highlights multidisciplinary approaches to weight management, combining endocrinology and obesity expertise to address metabolic complications, personalize therapeutic strategies, and improve long-term patient outcomes. Video: https://medic...

Dr. John Bernard Buse presents key updates from the joint ADA/EASD consensus report on the management of type 2 diabetes at the EASD 2026 Congress. This brief highlights updated clinical guidelines, person-centered management strategies, holistic care approaches, and evidence-based recommendations for glucose-lowering and cardiometabolic risk reduction. Video: https://medicaldigest.org/scientific-...

Dr. Cyrielle Caussy presents key insights from the EASD-EASL joint session on metabolic dysfunction-associated steatotic liver disease (MASLD) at the EASD 2026 Congress. This brief highlights early therapeutic approvals, real-world clinical data, and novel emerging treatments aimed at optimizing multidisciplinary care and improving outcomes for patients with MASLD and metabolic risk factors. Video...

Dr. Paolo Sbraccia presents key insights into viewing obesity as a systemic disease and adopting a biology-driven approach to metabolic health at the EASD 2026 Congress. This brief highlights the pathophysiological progression from adiposity to systemic metabolic dysfunction, emphasizing targeted therapies and clinical strategies that look beyond weight loss to optimize overall cardiometabolic out...

Dr. Martin Haluzík presents key findings from the REIMAGINE 2 trial evaluating CagriSema at the EASD 2026 Congress. This brief highlights clinical data on the impact of dual amylin and GLP-1 receptor agonism on bone turnover markers, overall bone health, and metabolic parameters in participants with inadequately controlled type 2 diabetes. Video: https://medicaldigest.org/scientific-contents/inter...

Dr. Stefano Del Prato presents key findings from the Phase 3 TRIUMPH-2 trial evaluating retatrutide at the EASD 2026 Congress. This brief highlights clinical evidence on the glycemic efficacy, weight reduction outcomes, and safety profile of triple receptor agonism in adults living with obesity and type 2 diabetes. Video: https://medicaldigest.org/scientific-contents/interview:retatrutide-adults-o...

Dr. Katherine Tuttle presents key insights on cardiorenal protection in type 2 diabetes at the EASD 2026 Congress, drawing from both the FLOW and ACHIEVE-4 trials. This brief highlights novel proteomic biomarker analyses explaining the pathways of kidney protection in FLOW, alongside clinical data from the ACHIEVE-4 trial comparing the renal outcomes of oral orforglipron versus insulin glargine in...

Dr. Akshay Jain presents key findings from the REIMAGINE 1 trial on CagriSema at the EASD 2026 Congress. This brief highlights clinical evidence on the efficacy of CagriSema in achieving composite HbA1c and significant body weight reduction targets, demonstrating the potential of dual-action therapy in managing type 2 diabetes and metabolic risk. Video: https://medicaldigest.org/scientific-content...

Dr. Arya Sharma presents key insights into reshaping the obesity treatment paradigm through early intervention at the EASD 2026 Congress. This brief highlights the long-term clinical benefits of proactive weight management, addressing the underlying drivers of metabolic disease early, and transitioning toward sustained, lifelong therapeutic approaches for obesity. Video: https://medicaldigest.org/...

Dr. Michael Roden presents key insights from the EASD-EASL joint session on metabolic dysfunction-associated steatotic liver disease (MASLD) at the EASD 2026 Congress. This brief highlights early therapeutic approvals, real-world clinical data, and novel emerging treatments aimed at optimizing multidisciplinary care and improving outcomes for patients with MASLD and metabolic risk factors. Video:...

Dr. Amisha Wallia presents key insights from the EASD-ADA joint session on closing the implementation gap in diabetes care at the EASD 2026 Congress. This brief highlights evidence-based implementation strategies, discussing pathways to overcome system-level barriers, translate clinical guidelines into routine practice, and achieve equitable care delivery for patients with diabetes. Video: https:/...

Prof. Oyvind H. Lie presents trial findings on antithrombotic management following transcatheter aortic valve implantation (TAVI) at the ESC Congress 2026, evaluating optimal regimen strategies to balance ischemic risk reduction and bleeding complications. Video: https://medicaldigest.org/scientific-contents/interview:acasa-tavi-antithrombotic-therapy-after-tavi